How many pounds a week can you lose on Wegovy?

What STEP 1 actually recorded, and how to read it

The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity across 68 weeks. Participants receiving semaglutide 2.4 mg lost an average of around 15% of their body weight compared with roughly 2.4% on placebo, alongside a reduced-calorie diet and increased physical activity. That is a meaningful difference. But 68 weeks divided into 15% of starting weight is where the "how many pounds a week" question gets interesting, and a little misleading if you take it at face value.

If someone starts at 100 kg and loses 15 kg over 68 weeks, the maths works out to roughly 0.22 kg (under half a pound) a week as a flat average. In practice the loss is front-loaded. Many people report noticeable drops in the first month or two (sometimes a pound or more a week) because appetite suppression arrives before the body fully adapts. By months nine to twelve, the weekly number often slows to a fraction of that as a new equilibrium approaches. Treating the average as a steady-state target will mislead you in both directions: too slow at the start, too fast at the end.

Useful context from the NHS semaglutide patient page: weight loss medicines work best alongside diet and activity changes, and individual results vary. That caveat is baked into every trial result too, STEP 1 participants were actively supported with lifestyle counselling throughout.

Where dose level fits the weekly picture

Wegovy is not dosed at full strength from day one. The titration schedule starts at 0.25 mg and steps up roughly every four weeks, reaching the 2.4 mg maintenance dose after about five months. During those earlier doses, most people notice modest appetite changes rather than dramatic weight loss. The clinical effect builds with the dose. So if someone asks how many pounds a week they should expect at week three on Wegovy, the honest answer is: probably not many, and that is by design, not failure.

The dose trajectory matters for expectation-setting. If progress feels slow in the first eight weeks, it is likely because you are still on a sub-therapeutic dose, not because the medicine is not working for you. Our guide to how many months Wegovy typically takes to produce meaningful results covers this timeline in more detail, including what most people notice at each stage.

For those who reach maintenance and still find progress slower than expected, there is now a licensed higher dose. The MHRA approved the 7.2 mg Wegovy pen in April 2026, with trial data suggesting around 20.7% average weight loss over 72 weeks, a figure closer to the results seen with the highest tirzepatide doses. Whether that option is appropriate for a given person is a clinical decision, not a self-selection one.

The factors that actually move your weekly number

Two people on identical Wegovy doses can lose very different amounts per week. Metabolism, starting BMI, muscle mass, sleep quality, alcohol intake, the specific calorie deficit achieved, and how much protein is kept in the diet all influence the rate. Appetite suppression from GLP-1 medicines can reduce overall calorie intake significantly, but it does not override energy balance entirely.

Protein adequacy is one of the more practically important variables. On a reduced appetite, it is easy to eat less protein than the body needs to preserve lean muscle, which can slow metabolic rate over time. Many people on Wegovy find keeping a high-protein food kept prominently in the fridge (Greek yoghurt on the door shelf, say) is the simplest nudge to hit their target without having to think hard about it.

If progress has stalled and you are confident about lifestyle factors, the question of whether dose, timing, or another variable is the issue is worth raising with a prescriber. Our page on losing only one pound a week on semaglutide covers the most common reasons a plateau sets in, and what options exist.

One area that catches people off guard: missed or late injections. Even a few days off schedule can affect the steady-state concentration of the medicine. If you are unsure how much flexibility the schedule allows, this guide to how many days you can miss Wegovy sets out what the guidance says, and when to contact your prescriber.

Putting the weekly rate in a longer context

Twelve weeks in, many people have lost between three and six kilograms (roughly six to thirteen pounds), though the range is wide. By six months, the average from trials sits closer to nine to eleven kilograms. By the end of 68 weeks, it is around fifteen kilograms at the 2.4 mg dose, further at 7.2 mg for those who progress there.

None of those numbers come with a guarantee. NICE's appraisal of semaglutide (TA875) notes that treatment should be reviewed if less than 5% weight loss is achieved after six months on the maintenance dose, a useful prompt for a clinical conversation rather than a reason for alarm.

The rate of loss also matters less than whether it is being maintained. A slower weekly number sustained over eighteen months beats a fast start that reverses. Explore our full Wegovy overview for a broader picture of how the medicine is used in practice, or read about semaglutide's mechanism and UK licensing if you want to understand why GLP-1 receptor agonism produces the appetite effects it does. If you are weighing up costs as part of your decision, the Wegovy pricing page sets out what private treatment typically involves.

If you want to know whether Wegovy is clinically suitable for you, the place to start is a proper clinical assessment. Check your eligibility with our prescribers, the consultation is free, and a GPhC-registered clinician reviews your answers the same day.